Search for content, post, videos

Nordic Nanovector, AREVA collaborates

nordic nanovector
Nordic Nanovector and AREVA Med, the AREVA medical subsidiary developing lead-212 (212Pb) based cancer therapies, have entered into a collaboration agreement to investigate the potential of a 212Pb-conjugated anti-CD37 antibody for the treatment of leukaemias. Leukemias are orphan diseases with a
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.